Patient-reported outcomes (PROs) in NRG Oncology RTOG 0436: a phase III trial evaluating the addition of cetuximab to paclitaxel, cisplatin, and radiation for esophageal cancer treated without surgery.

Autor: Kachnic LA; Department of Radiation Oncology, Columbia University Irving Medical Center, 622 West 168th Street, CHONY North, B Level, Room 11, New York, NY, 10032, USA. lak2187@cumc.columbia.edu., Winter K; NRG Oncology Statistics and Data Management Center, Philadelphia, PA, USA., Suntharalingam M; University of Maryland School of Medicine, Baltimore, MD, USA., Ilson D; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Konski A; University of Pennsylvania, Philadelphia, PA, USA., Lloyd S; University of Utah Health Science Center, Salt Lake City, UT, USA., McAvoy SA; University of Maryland/Greenebaum Cancer Center, Baltimore, MD, USA., Lad T; John H Stroger Jr Hospital of Cook County, Chicago, IL, USA., Olowokure OG; University of Cincinnati, Cincinnati, OH, USA., Samson P; Washington University, St. Louis, MO, USA., Gore EM; Medical College of Wisconsin and Zablocki VA Medical Center, Milwaukee, WI, USA., Meyer JE; Fox Chase Cancer Center, Philadelphia, PA, USA., Videtic GMM; Cleveland Clinic Foundation, Cleveland, OH, USA., Clump DA; UPMC-Shadyside Hospital, Pittsburgh, PA, USA., Raben A; Christiana Care Health Services, INC. CCOP, New Castle County, Delaware, USA., Kayaleh O; Orlando Health, Orlando, FL, USA., Barker J Jr; USON-Texas Oncology-Sugar Land, Sugar Land, TX, USA., Haddock MG; Mayo Clinic, Rochester, MN, USA., Hopkins JO; NCORP/Novant Health Cancer Institute, Winston-Salem, NC, USA., Bruner DW; Emory University, Atlanta, GA, USA.

Publikováno v: Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation [Qual Life Res] 2024 Oct; Vol. 33 (10), pp. 2833-2844. Date of Electronic Publication: 2024 Jul 27.